Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Purchased by Cinctive Capital Management LP

Cinctive Capital Management LP boosted its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 140.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 81,320 shares of the biopharmaceutical company’s stock after buying an additional 47,523 shares during the period. Cinctive Capital Management LP’s holdings in Celldex Therapeutics were worth $2,055,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC lifted its holdings in shares of Celldex Therapeutics by 215.7% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 878 shares during the period. Headlands Technologies LLC purchased a new stake in Celldex Therapeutics in the fourth quarter valued at approximately $81,000. KBC Group NV increased its position in Celldex Therapeutics by 79.1% during the fourth quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 1,647 shares during the last quarter. AlphaQuest LLC raised its stake in Celldex Therapeutics by 171.0% during the fourth quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 2,705 shares during the period. Finally, E Fund Management Co. Ltd. acquired a new position in shares of Celldex Therapeutics in the 4th quarter valued at $273,000.

Celldex Therapeutics Stock Up 3.1 %

Shares of NASDAQ:CLDX opened at $17.38 on Thursday. The company has a market capitalization of $1.15 billion, a price-to-earnings ratio of -6.76 and a beta of 1.76. The company has a 50 day moving average of $21.49 and a two-hundred day moving average of $25.81. Celldex Therapeutics, Inc. has a 52-week low of $16.40 and a 52-week high of $47.00.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.02. The firm had revenue of $1.18 million for the quarter, compared to analyst estimates of $1.25 million. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. On average, equities analysts anticipate that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $67.00 target price on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. The Goldman Sachs Group cut their price objective on Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating on the stock in a report on Monday, March 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research note on Friday, February 28th. Morgan Stanley assumed coverage on shares of Celldex Therapeutics in a research report on Thursday, March 20th. They set an “overweight” rating and a $46.00 target price for the company. Finally, UBS Group assumed coverage on shares of Celldex Therapeutics in a research report on Thursday, February 13th. They set a “buy” rating and a $44.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $54.33.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.